Related Experiment Video
Updated: May 27, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Monoclonal antibody therapies against anthrax
Zhaochun Chen1, Mahtab Moayeri, Robert Purcell
1Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. zchen@niaid.nih.gov
Monoclonal antibodies targeting Bacillus anthracis virulence factors, including toxins and capsule, are crucial for anthrax treatment. A combination therapy of these antibodies may offer enhanced therapeutic benefits against anthrax.
Area of Science:
- Microbiology
- Immunology
- Infectious Diseases
Background:
- Anthrax is a lethal disease caused by Bacillus anthracis.
- Virulence factors like toxins (protective antigen, lethal factor, edema factor) and capsule contribute to anthrax lethality.
- Anthrax poses risks as both a natural infection and a bioterrorism agent.
Purpose of the Study:
- To review the development of monoclonal antibodies (mAbs) against anthrax virulence factors.
- To evaluate the therapeutic potential of anti-anthrax mAbs.
- To advocate for combination mAb therapy for anthrax.
Main Methods:
- Review of current research on anti-anthrax monoclonal antibody development.
- Analysis of virulence factors targeted by mAbs: protective antigen (PA), lethal factor (LF), edema factor (EF), and capsule.
- Assessment of therapeutic strategies involving mAbs.
Main Results:
- Significant progress has been made in generating therapeutic mAbs against key anthrax virulence factors.
- mAbs targeting PA, LF, EF, and the B. anthracis capsule have been developed.
- The review highlights the potential of these mAbs in combating anthrax.
Conclusions:
- Monoclonal antibodies represent a promising therapeutic avenue for anthrax.
- A combination therapy using mAbs targeting diverse epitopes or virulence factors could provide superior protection against anthrax.
- Further development of anti-anthrax mAb cocktails is warranted.
More Related Videos
09:45Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
Published on: May 18, 2021
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Inhalation Anthrax
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Clinical Significance of Antibiotic Resistance
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...